Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged at the end of 2019 and by mid-June 2020 the virus had spread to at least 215 countries, caused more than 8 000 000 confirmed infections and over 450 000 deaths, and overwhelmed healthcare systems worldwide. Like severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 and caused a similar disease, SARS-CoV-2 is a betacoronavirus. Both viruses use human angiotensin-converting enzyme 2 (hACE2) as a receptor to enter cells. However, the SARS-CoV-2 spike (S) glycoprotein has a novel insertion that generates a putative furin cleavage signal and this has been postulated to expand the host range. Two low-passage (P) strains of SARS-CoV-2 (Wash1 : P4 and Munich : P1) were cultured twice in Vero E6 cells and characterized virologically. Sanger and MinION sequencing demonstrated significant deletions in the furin cleavage signal of Wash1 : P6 and minor variants in the Munich : P3 strain. Cleavage of the S glycoprotein in SARS-CoV-2-infected Vero E6 cell lysates was inefficient even when an intact furin cleavage signal was present. Indirect immunofluorescence demonstrated that the S glycoprotein reached the cell surface. Since the S protein is a major antigenic target for the development of neutralizing antibodies, we investigated the development of neutralizing antibody titres in serial serum samples obtained from COVID-19 human patients. These were comparable regardless of the presence of an intact or deleted furin cleavage signal. These studies illustrate the need to characterize virus stocks meticulously prior to performing either in vitro or in vivo pathogenesis studies.
【저자키워드】 COVID-19, SARS-CoV-2, neutralization, clinical isolates, furin cleavage, adaptation, 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, Coronavirus disease 2019, coronavirus, Pathogenesis, S protein, Neutralizing antibodies, furin, SARS-CoV, Sequencing, variant, Infection, in vitro, severe acute respiratory syndrome Coronavirus, virus, Betacoronavirus, hACE2, cells, Deletion, MinION, cleavage, host range, VERO E6 cells, glycoprotein, receptor, respiratory, Vero E6 cell, in vivo, disease, patients, SARS-CoV-2 spike, S glycoprotein, Human angiotensin-converting enzyme 2, angiotensin, strain, deaths, Munich, Healthcare system, Vero E6, the cell, causative agent, indirect immunofluorescence, Healthcare systems, acute respiratory syndrome, acute respiratory syndrome coronavirus, cell surface, human Angiotensin-converting enzyme, virus stocks, both viruses, insertion, serum sample, neutralizing antibody titres, Cell, caused, virus, spread to, investigated, generate, characterized, demonstrated, Like, comparable, the S protein, reached, deleted, virus stock, expand, inefficient, antigenic target, cell lysate, neutralizing antibody titre, the SARS-CoV-2, 【제목키워드】 serum, hospitalized COVID-19 patient, growth,